18.11.2026 • News

BASF Backtracks: No Takeover of Evonik

After the state government of North Rhine-Westphalia publicly opposed a takeover of Evonik by BASF, the Ludwigshafen, Germany-based chemical company has ended its efforts to acquire its Essen-based competitor.

flags of both companies
© BASF, Evonik

In an official press release, BASF announced that it had ended its attempt to acquire Evonik. The decision follows Evonik’s rejection of two non-binding cash offers. Although BASF had signaled its willingness to make a further moderate increase in the offer, Evonik’s Executive Board rejected a substantial exchange. At the same time, Evonik’s independent business outlook and the associated risks did not provide a sufficient basis for BASF to justify a higher valuation. Against this backdrop, BASF believes that it would not be in the best interest of its shareholders to pursue the transaction at a higher price.

It is not known to what extent the publicly stated opposition of North Rhine-Westphalia Minister-President Hendrik Wüst and Minister of Economic Affairs Mona Neubaur influenced the decision in Ludwigshafen. Both spoke out in favor of the independence of the Essen-based specialty chemicals group. Wüst stated that he wanted “this industrial core to remain here in North Rhine-Westphalia.” He said he viewed a potential takeover as “very skeptical, to put it mildly.” He cited the approximately 11,000 Evonik employees in North Rhine-Westphalia. Economic Affairs Minister Neubaur was even more explicit in her comments to Reuters: “We reject a takeover by BASF.” She added that Evonik is best positioned to shape its own future based on the course it has set.

BASF’s interest in Evonik first became public at the end of September and was confirmed by both sides. According to media reports, BASF had most recently submitted an offer of €24 per Evonik share, which would correspond to an equity valuation of approximately €11.2 billion. BASF has now confirmed this offer. CEO Markus Kamieth stated: “We are convinced that BASF’s cash offer of €24 per share would have represented significant additional and secure value for Evonik’s shareholders.” He added: “We continue to believe that the merger under BASF’s ownership would create a stronger chemical company that would deliver additional value to shareholders as well as benefits for the employees and customers of the combined company.”

As part of its Winning Ways strategy, BASF has consistently emphasized that acquisitions to strengthen and expand its core businesses are an option, but not a necessity. By ending its efforts to acquire Evonik, the company underscores its commitment to disciplined capital allocation and attractive dividends for shareholders.


Company

Logo:

BASF SE

Carl-Bosch-Straße 38
67056 Ludwigshafen
Germany

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.